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Introduction
Duffy gene (FY) polymorphism is prominent historically in many corners of biomedical investigation. In 1968, Donahue et al used Fya/ Fyb serological inheritance patterns and human chromosome 1 centromeric staining features to make FY the first gene mapped to a human autosome (1). Similarly, the Duffy blood group protein (Fy) (2) was the first identified member of the diverse seven transmembrane chemokine receptor family, albeit with a number of interesting structural and functional differences that make its biology unique (2). Fy expression on both erythroid and non-erythroid cells (2) modulates homeostatic levels and gradients of chemokines between blood circulation (3-7) and tissues (8) (9) (10) (11) (12) underlying immune responses and an emerging array of pathologies.
The decades-long observations that Africans and African-Americans, who are for the most part Fy-negative, were highly resistant to Plasmodium vivax blood stage infection (13) (14) (15) (16) (17) (18) suggested that interaction with the Fy protein was required for parasite invasion of human red blood cells (RBCs) (19) . With gene sequencing, a single nucleotide polymorphism (SNP) in the FY gene GATA-1 transcription factor binding site has been shown to block FY erythroid expression (20, 21) and homozygosity underlies the "Fy erythrocyte silent" (herein, Fy-negative) phenotype characterized by standard serological methods (20) . In vitro studies using Fy-dependent, P.
knowlesi (22, 23) , have gone on to show that while the merozoite is able to orient apically to the RBC surface, the mechanism fails to establish parasite-Fy-negative RBC commitment. Therefore, onward formation of a tight mobile junction needed to infect the RBC was inhibited, and invasion was blocked (24). This background has inextricably linked Duffy blood group genetics and malaria.
Recent studies now report P. vivax infections in Fy-negative individuals from many malarious countries across Africa (25) . These observations lead to at least two hypotheses. First, the parasite's Duffy binding protein (PvDBP) may not interact with Fy, exclusively. Second, constitutive low level or periodic Fy expression may occur in Fy-negative people and facilitate blood stage infection.
Previous studies have demonstrated a gene dosage effect of the FY GATA-1 SNP that reduces erythrocyte surface expression of Fy a and Fy b by 50% in heterozygous individuals (21, 26) , and others have identified additional coding region SNPs associated with reduced expression of both Fy a (Fy a -weak) (27) and Fy b (Fy b -weak) (28-30); very rare nonsense SNPs and deletions in the FY gene coding region have also been reported (see text with Supplemental Information (SI) Table S1) (31, 32) . Further, Fy is more highly expressed on reticulocytes vs. older RBC (26) . With the range of Fy expression phenotypes, here we tested the hypothesis that Fy protein expression may not be fully blocked by the GATA-1 SNP (FY ES mutation) as demonstrated through previous study designs (33, 34) .
Results

Binding specificity of CA111
To assess the presence of Fy on RBCs, the camelid single-domain antibody CA111 was used.
This VHH or nanobody is specific for the 5-amino acid sequence 22 FEDVW 26 within the Fy amino terminal domain, overlapping the linear epitope recognized by the anti-Fy6, 2C3 mouse MoAb (Supplemental Methods; Text S1) (35) . This is the same region of Fy to which chemokines and PvDBP bind and acts as the receptor for P. vivax RBC invasion (35) . In specificity assessments, we demonstrate that the anti-Fy6 antibodies CA111 and 2C3, reciprocally inhibit their binding to Fy-positive pbRBCs in competitive binding studies ( Figure   S1A ). Additional comparisons among CA111, 2C3, anti-Fya and anti-Fyb show that CA111 demonstrates the strongest relative sensitivity for Fy binding among these antibody reagents ( Figure S1B) . Finally, while in silico analysis (BLASTp) showed the Fy 22 FEDVW 26 and CXCR2 11 FEDFW 15 sequence motifs vary at only one position, we demonstrated that CA111 was not able to bind or to pull down CXCR2 (Figure S2) .
We then tested whether CA111 recognized Fy on FY*A/*A, FY*B/*B and FY*B ES /*B ES RBC.
Working on freshly collected, peripheral blood red blood cells (pbRBC), we observed expected binding to pbRBC of FY*A/*A, FY*B/*B donors, but also observed unexpected CA111 binding to FY*B ES /*B ES pbRBC (Figure 1) . Over three different time points of our initial experiments, the CA111 binding varied from 74.0% to 89.4% in FY*B/*B pbRBC, from 77.2% to 90.8% in FY*A/*A pbRBC and from 11.5% to 47.6% in FY*B ES /*B ES . This latter result, observed several times and tested in triplicate, was markedly higher than previously observed on FY*B ES /*B ES donors(35), and suggested that the Fy protein may be expressed periodically on the RBC surface of FY*B ES /*B ES (Donor #1).
rPvDBPII binding on FY*B ES /*B ES peripheral blood RBC
We next tested if rPvDBPII would interact with FY*B ES /*B ES (Donor #1) pbRBCs. rPvDBPII bound to both FY*A/*B and to a lesser extent FY*B ES /*B ES (Donor #1) pbRBC. As a control, unfolded rPvDBPII failed to bind pbRBC from the same donors (Figure 2) . rPvDBPII, as well as chemokine binding to Fy have been shown to be sensitive to chymotrypsin treatment of pbRBC (22, 36) . Consistent with expectations from these previous studies, we observed that chymotrypsin treatment eliminated rPvDBPII binding to pbRBC from both FY*A/*B and FY*B ES /*B ES donors.
Specificity of rPvDBPII binding on FY*B ES /*B ES pbRBC
Given the unexpected interaction of both CA111 and rPvDBPII with FY*B ES /*B ES pbRBC, we pursued additional experiments to further evaluate the specificity of rPvDBPII binding. We first evaluated the specificity of this interaction by testing rPvDBPII binding to Fy-positive and Fynegative pbRBC by Western blot analysis (Figure 3A ).
We exposed both Fy-positive and Fy-negative pbRBC to rPvDBPII, eluted pbRBC bound proteins and then probed a Western blot of these proteins with a polyclonal antibody to PvDBP.
Western blot results revealed a single protein band from both FY*A/*B and FY*B ES /*B ES pbRBC ( Figure 3A) ; specific detection by the polyclonal anti-PvDBP and the apparent molecular weight of approximately 35kDa were both consistent with detection of the rPvDBPII protein.
To evaluate the relative affinity of rPvDBPII interaction to Fy-positive and Fy-negative pbRBC, we next tested the dissociation of PvDBPII from pbRBC with increasing NaCl concentrations ( Figure 3B) . While we observed that the relative binding of rPvDBPII to FY*B ES /*B ES pbRBC was markedly lower than that observed for FY*B/*B and FY*A/*B, dissociation of rPvDBPII from FY*B/*B and FY*A/*B versus FY*B ES /*B ES pbRBC was similar across decreasing NaCl concentrations (0.15M, 0.3M, 0.6M and 1M NaCl). At 1.5M NaCl the pbRBC for all FY genotypes were lysing and therefore rPvDBPII signal decreased across all samples.
Given consistent demonstration of the chymotrypsin-sensitive nature of the Fy protein (22, 33, (36) (37) (38) and the molecular interactions tethered to RBC Fy, we tested the reproducibility of rPvDBPII binding to FY*B ES /*B ES pbRBC after chymotrypsin treatment. Here, we examined the chymotrypsin sensitivity of rPvDBPII binding for one FY*A/*B and FY*B ES /*B ES (Donor #1) at multiple independent times and results (Figure 4) consistently showed that the binding of rPvDBPII to both FY*A/*B and FY*B ES /*B ES pbRBC were significantly higher before than after a chymotrypsin treatment; consistent with results in Figure 1 , we observed that rPvDBPII binding to Fy varied for the individual donors between different time points.
rPvDBPII binding on RBC over time
Because we observed variation in CA111 and PvDBPII binding to pbRBC at different time points for both Fy-positive and Fy-negative donors, we examined this variability in greater detail using comparable staining and flow cytometric procedures (Figure 5A) . Among the FY*B ES /*B ES pbRBC sampling time points (8 samples for both FY*B ES /*B ES #1 and FY*B ES /*B ES #2), five samples showed rPvDBPII binding at least 2-fold above the negative control; both FY*B ES /*B ES donors showed evidence of rPvDBPII 5-fold above the negative control. Interestingly, rPvDBPII binding was also variable for Fy-positive individuals, irrespective of their genotype. Overall, the rPvDBPII binding (fold-increase over negative control) was 32.4 for FY*B/*B (11.8; 110.9); 17.2 for FY*A/*A (4.9; 47.7); 1.9 for FY*B ES /*B ES #1 (0.7; 5.9); 2.4 for FY*B ES /*B ES #2 (0.5; 6.7). Of additional interest, across this series of samples from the four pbRBC donors featured, the higher levels of Fy expression on FY*B ES /*B ES pbRBC were comparable to the lower level of rPvDBPII binding for the FY*A/*A pbRBC (Figure 5A ; see *).
To confirm the specificity of rPvDBPII binding to pbRBC, we used CA111 to bind available Fy protein on the pbRBC and thereby block rPvDBPII access to the RBC. In a second set of experiments we used the Fy recombinant protein fused to the Fc region of IgG1, nDARCIg(39), to block rPvDBPII binding on the pbRBC surface ( Figure 5B ). For these experiments, we tested one FY*B/*B, one FY*A/*A and two FY*B ES /*B ES donors (#1 and #2) at multiple time points. For the Fy-positive donors, the Fy-specific CA111 nanobody (Figure 5B left panel) decreased rPvDBPII binding from 25.2-fold (5.8; 110.9) over negative controls to 2.1-fold (0.2; 12.1) (P-value =0.001 for FY*B/*B; P-value =0.001 for FY*A/*A). Under these same conditions, rPvDBPII binding decreased for the FY*B ES /*B ES pbRBC from 2.0-fold (0.5;6.4) over negative controls to 0.8-fold (0.2;1.9) (P-value =0.002 for FY*B ES /*B ES #1; P-value =0.003 for FY*B ES /*B ES #2).
In partner experiments to assess the specificity of rPvDBPII binding to pbRBC (Figure 5B right panel), nDARCIg was observed to decrease rPvDBPII binding from 25.2-fold (5.8; 110.9) over negative controls to 2.81-fold (0.5;7.7) (P-value=0.004 for FY*B/*B; P-value=0.004 for FY*A/*A).
For the FY*B ES /*B ES pbRBC, nDARC decreased rPvDBPII binding to pbRBC from 2.0-fold (0.5;6.4) over negative controls to 1.0-fold (0.3;2.8). Thus, both CA111 and nDARCIg blocked binding of PvDBPII to FY*B ES /*B ES pbRBCs, providing evidence of Fy-specific binding of PvDBPII to FY*B ES /*B ES pbRBC.
As further evidence of Fy protein expression on the FY*B ES /*B ES pbRBC surface, we solubilized pbRBC membranes and immunoprecipitated the Fy protein using CA111. Results show that following CA111-capture, we successfully detected the Fy protein on Western blots probed with a second Fy-specific antibody (polyclonal anti-ACKR1) from one FY*B/*B and both FY*B ES /*B ES donors ( Figure 5C ).
Interrogating Fy protein expression on erythroid progenitor cells in vitro
Given a wide range of results pointing to P. vivax preference for infection of reticulocytes (40-48) and the apparent low, variable expression Fy protein on Fy*B ES /*B ES pbRBC, we postulated that this expression pattern may reflect the lower and declining stages of Fy expression on aging pbRBC. Further recent evidence from murine studies showing that the Fy protein is expressed at higher levels on pro-erythroblasts and normoblasts, compared to mature RBC (49), suggesting that we should investigated Fy expression in erythroid precursors. We initiated these in vitro studies by expanding CD34 pos (expressed on megakaryocyte/erythrocyte progenitors (MEP (50-54))) from the peripheral blood of one previous FY*B/*B donor and FY*B ES /*B ES Donors #1 and #2. At Days 11, 15 and 18, cells were collected to monitor erythroid lineage maturation using the surface markers CD36, CD71, Glycophorin A and Band 3 and query Fy protein expression ( Figure 6A and Figure S3A ). As expected, during the differentiation process, CD36 and CD71 were decreasing, whereas Glycophorin A and Band 3 increased among the most mature RBCs. No difference in the maturation stages from the different donors was observed over time ( Figure S3B) . Expression of the Fy protein during (Figure 6B and 6C) .
These studies confirm the ability of individuals with FY*B ES /*B ES genotype to clearly express the Fy protein in erythroid progenitor cells cultured in vitro; these results required confirmation of Fy expression in erythroid progenitor cells ex vivo.
Ex vivo Fy protein expression on bone marrow erythroid precursors.
The erythroid developmental stages observed during in vitro CD34 cell expansion studies are most commonly found in the bone marrow in vivo. Therefore, to evaluate Fy expression in human bone marrow, we monitored expression ex vivo of the following cell surface markers as accepted indicators erythroid precursors: CD34 (marker of MEP cells (50-54)), CD45 (marker to differentiate erythroid from lymphoid development (50)), CD105 (marker human erythrocyte progenitor (hEP) (54-56)), and CD71 (marker of reticulocytes (57) 
Discussion
Given our findings on P. vivax infection of Fy-negative people from Madagascar (58) and other malarious sites across Africa (25), we wanted to investigate how parasite and host invasion proteins interacted with Fy-negative RBCs. To initiate these studies, it was necessary to change how we have performed erythrocyte binding assays (34). Given that Fy-negatives are infected with P. vivax, we cannot assume that Fy-specific antibodies or rPvDBPII do not bind to Fynegative RBC (22, 33, 59, 60) . Additionally, because we have observed examples of varying Fy expression (King and Zimmerman; unpublished data), it was necessary to conduct a time series study to document fluctuation of Fy expression on both Fy-positive and Fy-negative RBC. This approach revealed novel findings from the outset of our studies, that the Fy protein is expressed on genotypically Fy-negative erythroid cells.
Our initial studies focused on peripheral blood RBCs (pbRBC), showed that Fy expression on Fy-negative pbRBC was periodically positive and that these RBC could interact with rPvDBPII at levels similar to RBC from FY*A/*A people. Well aware that numerous studies point to P. vivax preference for infection of reticulocytes (40, (42) (43) (44) (45) (46) (47) (48) , we were interested to study Fy expression Our first studies on earlier erythroid stages focused on enriching CD34 pos MEPs that circulate in the peripheral blood, allowing them to mature in vitro under conditions favoring erythroid development(51). We purposefully included the same Fy-positive and Fy-negative people from our work demonstrating pbRBC CA111 and rPvDBPII binding to provide continuity across our study design. We felt it was particularly important to continue study of the same Fy-negative donors so that we could bridge observations from early erythroid development to mature erythrocytes. Interestingly, results showed that significantly higher proportions of the erythroid precursor cells from FY*B ES /*B ES donors were Fy protein-positive than their pbRBC.
With observation of Fy protein expression from the CD34 cell maturation experiments, the logical in vivo extension of this investigation was to repeat our studies on bone marrow samples as the site for natural erythroid cell development. After identification of a strategy to segregate the earliest multipotent stem cells (CD34 pos ) differentiating toward erythroid (CD105 pos ) and not lymphoid (CD105 neg ) development, we continued to monitor expression of CD71 and Band 3 as markers distinguishing reticulocyte maturation. Results from these bone marrow studies showed Fy protein expression on early stage cells committing to erythroid development in both Fypositive and Fy-negative people. Our observations suggest that Fy expression initiates in an early erythroid subpopulation (CD34 pos /CD45 pos /CD105 pos /CD71 neg /Band3 neg ) in both Fy-positive and Fy-negative people. This may suggest that Fy expression is driven by GATA-2, prior to proerythroblast differentiation and transition to 62) . The observed decline of Fy signal in CD34 neg /CD45 neg /CD105 neg /CD71 pos /Band3 pos cells, appears to be consistent with RBC extrusion of its nucleus, after which RBC precursors are no longer able to express their genes and the cell can only be equipped with the gene products expressed prior this important developmental event. With compromised FY gene expression associated with the GATA-1, FY ES SNP, the amount of Fy protein begins to decay early and from a lower surface concentration from Fy-negative than Fy-positive erythroid cells. Our results suggest Fy6specific CA111 is more sensitive than antibodies used in conventional serological typing.
Potential that bone marrow could be the source for reticulocytes for in vitro cell culture is becoming an increasingly important area of P. vivax research. Fernandez-Becerra et al. have expanded CD34 pos hematopoietic stem cells to generate CD71 pos reticulocytes for in vitro P. vivax culture (63). Others have concentrated their efforts on enriching reticulocytes from cord blood. Optimizing these in vitro culture systems will require additional trials as the importance of adult versus fetal hemoglobin, reticulocyte cell structure complexity and Duffy blood group polymorphism are addressed (64, 65).
Because our studies in Madagascar suggested that P. vivax had developed an Fy-independent RBC invasion mechanism (58), we were also interested to see that rPvDBPII binds to the surface of the different erythroid target cells used in our studies (pbRBC; expanded CD34 cell populations; bone marrow). We were further interested in the outcomes of our competitive inhibition studies. These experiments showed that addition of both CA111 and nDARCIg significantly reduced rPvDBPII binding to Fy-positive pbRBC and essentially blocked rPvDBPII binding to Fy-negative pbRBC. These latter results suggest that rPvDBPII binding may be limited to the Fy protein. If there were additional, equally attractive erythrocyte membrane proteins with which to interact, it is difficult to conclude how CA111 and nDARCIg inhibition of rPvDBPII binding could have been as complete.
Conclusion -Our findings present evidence that the FY GATA-1 promoter SNP does not fully abolish erythroid lineage Fy protein expression. With increasing evidence that Fy-negative people are not completely resistant to P. vivax blood stage malaria (25), new reservoirs of P.
vivax within infected individuals must be considered (47, 61) . Beyond gaining new insight on RBC invasion, it is important to understand the mechanisms of pathogenesis and clinical implications of P. vivax malaria in the bone marrow. With extensive involvement of the bone marrow, it becomes easier to understand how significant anemia can result from P. vivax malaria. At the very least, peripheral blood infection may significantly underestimate the total body parasitemia of a P. vivax infection (66). Finally, to gain a full appreciation of the global burden of vivax malaria (67, 68), further study is required to understand how the parasite uses the poorly understood reservoir of Fy-negative people to propagate and generate gametocytes that contribute to on-going transmission.
Methods
Study Participants and Sample collection
Study protocols were approved by the University Hospitals of Cleveland Institutional Review Board (#08-03-33 and #09-90-195). We included eleven Fy-positive (three females and eight males) and sixteen Fy-negative persons (nine females and seven males) (Table S1); all Fynegative persons were homozygous for the negative GATA-1 mutation (rs2814778; FY*B ES /*B ES ). All blood and bone marrow samples were processed within 2 hours of collection.
DNA Extraction and PCR-based Genotyping
All study participants were genotyped by previously described methods (58) (69)) Region II of Salvador I strain PvDBP (rPvDBPII; 37.6 KDa) was expressed as inclusion bodies in Escherichia coli and then refolded and purified as previously described (70-72). The protein purified before refolding served as a negative control.
Duffy Antigen Receptor for Chemokine chimeric protein construct (nDARCIg Fy b )
Briefly, as previously described (39), HEK293H cells were co-transfected with pCDM8-DARC-Fc (first N-terminal 60 amino acids of Fy) and pRc/CMV-TPST (human sulfotransferase).
Erythrocyte binding assays
Erythrocyte binding assays were performed based on previously developed strategies and reagents (34, 60); details provided in Supplemental Methods. In our studies, we also compare Multiple flow cytometry strategies were followed according to specific applications in this study.
Experiments evaluated CA111 and rPvDBPII binding to pbRBC in a total of 100,000 cells (all samples analyzed in triplicate). Erythrocyte binding assays were optimized by adjusting the blocking concentrations for BSA ( Figure S1A ) and through the use of unfolded rPvDBPII as a negative control (Figure S1B) . Additionally, our assay development also tested Fy protein expression on FY transfected/non-transfected K562 cells (75) (expressing/not expressing, respectively [ Figure S1C] ). Following experiments on the maturation of CD34+ hematopoietic stem cells, flow cytometry evaluated at least 50,000 cells (see Figure S3 ). In evaluation of bone marrow, at least 500,000 cells were evaluated to ensure sufficient data capture for erythroid precursor subpopulations of interest.
rPvDBPII Erythrocyte Capture Assay
This assay was previously described(76). Briefly, ~10 6 cells were collected from packed RBC and 10 µg of recombinant PvDBPII was added. After 2 hours of incubation at room temperature, the preparation was layered on top of 500 µL of dibutylphtalate and centrifuged at 11,000 rpm for 30 sec. The pellet was collected and the proteins bound at the RBC surface were eluted adding 20 µL of 1.5 M NaCl drop wise and shaking. After incubation (5 min), this procedure was repeated with 1.0 M of NaCl and then 0.3 M of NaCl. The preparation was centrifuged at 14,000 rpm for 2 min. The supernatant was collected and the proteins were separated on a Tris-Glycine SDS 4-20% gel (Biorad) in reducing conditions and then transferred onto a PVDF membrane.
The membrane was blocked for one hour with TBS 0.1% tween, 5% milk, incubated with rabbit anti-PvDBPII (1: 2,000), washed, then followed by the secondary antibody anti-rabbit HRP (Thermo Scientific). Chemiluminescent signal was detected using SuperSignal™ (Pierce) on Xray film. 
Erythroid differentiation of CD34 positive cells
Bone marrow cell preparation and staining
Fresh bone marrow was collected in heparin. Erythroid precursors were isolated by Ficoll Paque Plus. A panel constituted by CD45 PerCP Cy5.5, CD71 APC Cy7, CD34 FITC, Band3 PE and CD105 APC markers were used to differentiate erythroid precursors in bone marrow.
Erythroid cell protein extraction and Western blot analysis
Extracting the Fy protein from the surface of erythroid cells was conducted to specifically capture evidence of FY gene expression. These experiments were performed on pbRBCs from 
Statistical Methods
Statistical analyses were performed using STATA version 13.0
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Parts B and C. Expression of Fy protein in FY*B ES /*B ES erythroid precursors during differentiation in vitro detected by Western Blot. Erythroid differentiation was initiated from CD34 positive cells isolated from peripheral blood (B) or bone marrow (C). Cells were harvested on Day18 and Fy protein was immunoprecipitated (2.0x10 5 erythroid progenitors from both Fy-positive and Fy-negative); leukocyte depletion was not necessary as protocols for expansion of CD34 cells deplete peripheral blood leukocytes. The proteins captured by CA111 were revealed with a polyclonal anti-ACKR1 antibody (arrows). All the antibodies used to reveal the Fy protein signal were different between flow cytometry and Western blot. In the bone marrow, all stages of erythroid precursors are present except mature erythrocytes (that are circulating in the peripheral blood). To determine whether a particular erythroid developmental stage expressed the Fy protein (and monitor relative expression levels), we added a panel of 5 extra-cellular markers known to distinguish bone marrow lineages. The xaxis represents the signal of those markers defining the erythroid population. The Fy protein was detected by CA111 binding. For each point, the fold-increase over negative control of the geometric mean fluorescence intensity is represented with its standard deviation. Panel B. Two Fy-negative (in red [BM766 and BM864]) and two Fy-positive (in blue [BM565 and BM735]) bone marrows. Similar to Panel A, we added a panel of 5 extra-cellular markers known to distinguish bone marrow lineages. The x-axis represents the signal of those markers defining the erythroid population. The Fy protein was detected by 2C3 binding. For each point, the fold-increase over negative control of the geometric mean fluorescence intensity is shown. Note that BM735 is a heterozygous carrier of the Fy-negative allele (FY*A/*B ES ); BM565 is heterozygous for both Fypositive alleles (FY*A/*B).
Panel C. Expression of Fy protein in Fy*B ES /*B ES CD45 negative erythroid precursors from ex vivo bone marrow. CD45 negative cells (erythroid precursors in bone marrow) of three bone marrow samples were sorted by flow cytometry. The membrane proteins of the sorted cells were then immunoprecipitated with the CA111 and revealed by Western Blot with a polyclonal anti-ACKR1 antibody (arrow). Both Fy-positive and Fy-negative show a signal for the Fy protein in erythroid precursors. Fy protein was immunoprecipitated from bone marrow shown to be CD45 neg (2.0x10 5 erythroid progenitors from both Fy-positive and Fy-negative); leukocyte depletion was not. On the same samples, the immunoprecipitated proteins were probed with an anti-CXCR2 (see Supplemental Figure 2B ) and did not show any signal, meaning that CXCR2 is not expressed on CD45 negative erythroid precursors from bone marrow. 
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